FENNEC PHARMACEUTICALS INC. FENC Cash Flow

Fennec pharmaceuticals inc. (FENC)

CashFlow / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11
Operating activities:
Net loss
-13,975	-12,775	-12,149	-13,089	-10,946	-9,888	-9,194	-8,797	-7,808	-7,046	-5,899	-4,049	-3,175	-2,789	-2,186	-1,807	-1,256	-659	1,269	1,772	1,195	-2,176	-2,452	-4,598	2,759	1,845	-5,779	-4,777	-11,986	-5,163	4,857	2,477	2,731	4,685	0	0	0
Adjustments to reconcile net loss to net cash used in operating activities:
Unrealized (gain)/loss on derivatives
-	-	0	0	-	167	373	190	70	-134	-337	-135	-32	48	56	253	655	1,237	1,845	1,810	0	-	0	0	-	3,777	0	0	0	-	0	0	-	-	0	0	-
Amortization of deferred issuance cost
69	64	46	29	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gain on derivative settlement
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	-	-	-	-	-	-	-	0	-	-	-	0
Unrealized gain on derivative settlement
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-
Depreciation and amortization
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0
Non-cash settlement of Cadherin litigation
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0
Unrealized foreign exchange loss
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	6	6	19	9	0	0	0
Loss on impairment of capital assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0
Amortization of deferred lease inducements
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0
Non-cash severance
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	0	0	-	-	-	-	-
Non-cash severance expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0
Stock-based compensation - contractors
395	417	424	449	201	272	432	596	799	741	582	400	131	88	58	30	13	0	183	305	305	434	249	154	154	25	141	117	152	152	81	107	121	121	0	0	0
Stock-based compensation - employees
2,835	2,665	2,426	2,334	1,872	1,825	1,711	2,396	1,650	1,517	1,872	1,006	656	615	221	189	88	97	116	174	503	627	531	505	195	62	227	186	174	174	17	146	129	129	0	0	0
Changes in operating assets and liabilities:
Prepaid assets
112	58	-24	-4	1	40	213	39	75	85	157	3	-8	-33	-42	4	9	28	16	-11	-23	-33	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Other assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-1	9	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Other current assets
0	-	0	0	0	-	0	0	0	-	0	0	0	-	0	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accounts payable
377	580	-1,078	519	265	177	1,374	413	808	611	256	-50	-1	-54	-17	-56	-159	-11	-112	67	230	96	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Accrued liabilities
79	54	-93	-13	13	-17	45	44	8	497	77	44	51	33	2	1	36	-40	48	13	-12	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1,902	-1,943	-1,862	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Acquired in-process research and development
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0
Changes in operating assets and liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	365	53	-322	-374	-280	2,480	2,247	0	81	0	0	0
Net cash used in operating activities
-10,330	-9,060	-10,400	-9,764	-8,578	-7,826	-6,216	-5,575	-4,693	-3,641	0	0	0	-	0	-	-	-	-	-	-	-	-1,676	-1,702	-2,181	-2,210	-2,322	-2,579	-2,823	-2,994	-5,751	-5,661	-2,756	-3,226	0	0	0
Purchase of capital assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0
Disposal of capital assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0
Proceeds from sale of assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0
Release of restricted cash
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-
Release of restricted cash
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0
Restricted cash
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0
Purchase of short-term investments
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0
Redemption of short-term investments
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0
Investment in Cadherin Biomedical Inc.
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0
Acquired intellectual property rights
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0
Net cash used in investing activity
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Financing activities:
Capitalized deferred issuance cost
0	-	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in investing activity
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Options and warrants exercised
-	-	0	0	-	-	0	0	0	-	0	0	0	-	0	0	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Issuance of units, net of issue costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	-	-	0	0	-
Issuance of units, net of issue costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-
Cash paid for issuance costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0
Conversion of long-term debt to equity
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0
Long-term debt repayment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0
Capital lease repayments
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0
Issuance of shares, net of issuance costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	0	0	-	-	-	-	0	-	-	-	0
Short swing profit judgment offset with settlement expense
-	-	0	0	-	-	0	0	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Financing expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0
Proceeds from convertible note
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0
Other liability repayments
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0
Security deposits received
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0
Issuance of shares, options exercise
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	140	161	140	53	0	0	0	0	0	0	0	0	0	0	0	0
Private placement
-	-	-	-	-	-	-	-	-	-	0	0	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Rights offering
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by financing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5,129	572	497	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in financing activities
0	-71	1,116	1,599	2,090	2,347	21,052	20,983	28,161	27,975	0	0	0	-	0	-	-	-	-	-	-	-	1,731	1,710	1,623	1,570	0	0	0	0	2,566	2,566	2,566	2,566	0	0	0
Decrease in cash and cash equivalents
-10,330	-9,131	-8,657	-7,501	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Effect of exchange rate on cash and cash equivalents
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	-114	10	0	0	0
Decrease in cash and cash equivalents
-	-	-	-	-	-	-	-	23,468	24,334	5,151	5,151	2,706	2,984	3,171	3,227	-1,371	-1,365	773	839	578	644	55	8	-558	-640	-2,322	-2,579	-2,823	-2,994	-3,314	-3,224	-304	-650	0	0	0
Supplemental non-cash disclosure:
Non-cash deferred issuance cost (warrant value)
0	255	255	255	255	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-